Evidence map›Paper›PMID 36633717›Full record

ReviewThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2023

Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials.

Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Danial Habibi

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy: A Meta-analysis of Randomized Placebo-Controlled Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Myosin inhibitors for treatment of hypertrophic cardiomyopathy.The Cochrane database of systematic reviews · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mehrdad Rabiee RadSchool of Medicine, Isfahan University of Medical Science, Hezarjarib Ave, Isfahan, 81746-73461, Iran.
Ghazal Ghasempour DabaghiSchool of Medicine, Isfahan University of Medical Science, Hezarjarib Ave, Isfahan, 81746-73461, Iran. ghasempoorghazal@gmail.com.ORCID http://orcid.org/0000-0001-9850-874X
Danial HabibiDepartment of Biostatistics and Epidemiology, Faculty of Health, Isfahan University of Medical Science, Isfahan, Iran.
University of Isfahan · IRIsfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients. MAIN BODY: A total number of 539 patients were enrolled in four randomized clinical trials. The mean age of patients was 57.9 years and was followed for 29.3 weeks. Pooled analysis showed a significant improvement in clinical response (Log OR = 0.65; p = 0.01) and the number of patients with a reduction of ≥ 1 NYHA function class (Log OR = 0.64, p = 0.00). It was found that mavacamten did not significantly affect the Kansas City Cardiomyopathy Questionnaire (KCCQ) (SMD = 0.43, p = 0.08), peak oxygen uptake (PVO

conclusionsMavacamten proved to be effective and well-tolerated for the treatment of HCM. Mavacamten improved the signs and symptoms of HOCM and decreased EF in these patients without serious adverse events in the clinical trials.

Indexed as

HCMHOCMHypertrophic cardiomyopathyMavacamten

Identifiers

PMID36633717
PMCPMC9837360
OpenAlexW4315754011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.